Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial
Anne Hege Aamodt, Member Board of Directors at European Stroke Organisation, shared on LinkedIn:
”Published today in The New England Journal of Medicine: the TenCRAOS trial.
We asked a difficult but important question: can early intravenous thrombolysis with tenecteplase improve vision after acute central retinal artery occlusion?
In this randomized phase 3 trial, the answer was no — and treatment was associated with serious safety concerns.
Negative trials matter.
TenCRAOS provides much-needed high-level evidence in a field where treatment decisions are often made under great uncertainty.
These results should inform clinical practice and future guidelines.
Deeply grateful to our multidisciplinary teams in neurology and ophthalmology for an inspiring collaboration, and to all investigators, supporters, and funders — and especially to the patients who generously participated.”
Read the full article here.
Article: A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion
Authors: Stephen J. Ryan; Øystein Kalsnes Jørstad; Mona Skjelland; Maiju Pesonen; Claus Z. Simonsen; Toke Bek; Rolf Ankerlund Blauenfeldt, Anne Hege Aamodt et al., for the TenCRAOS Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet
-
Sep 29, 2026, 03:21Parvez Ahmed Chowdhury: Synthesizing Aspirin in the Organic Chemistry Lab
-
Sep 29, 2026, 03:12Ahmed Hamandi: Building the Future of Hematopoietic Transplantation in Iraq
-
Sep 29, 2026, 03:09M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
-
Sep 29, 2026, 03:07Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!